Conditions: Neuroendocrine Tumors Carcinoid Tumors Adrenal Gland Tumors Neuroblastoma Pancreatic Neuroendocrine Tumors Multiple Endocrine Neoplasia
Allocation: NA | Intervention model: SINGLE_GROUP
Enrollment: 4
Healthy volunteers: no

Brief summary:
To determine objective response rates (RR) by RECIST guideline version 1.1 for all patients treated with this strategy consisting of initial therapy with pertuzumab as a single agent and then addition of erlotinib for those who have stable disease or progressive disease at three months (Simon design).

Detailed description:

Arms:
arm 1: None

Interventions: intervention 1: pertuzumab intervention 2: erlotinib
Intervention descriptions: intervention 1: 840 mg, 420 mg, iv intervention 2: 150 mg, PO

Protocol document: